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Abstract
Analyzing outcomes in long-term cancer survivor studies can be complex. The effects of predictors on the failure
process may be difficult to assess over longer periods of time, as the commonly used assumption of proportionality
of hazards holding over an extended period is often questionable. In this manuscript, we compare seven different
survival models that estimate the hazard rate and the effects of proportional and non-proportional covariates.
In particular, we focus on an extension of the the multi-resolution hazard (MRH) estimator, combining a non-
proportional hierarchical MRH approach with a data-driven pruning algorithm that allows for computational
efficiency and produces robust estimates even in times of few observed failures. Using data from a large-scale ran-
domized prostate cancer clinical trial, we examine patterns of biochemical failure and estimate the time-varying
effects of androgen deprivation therapy treatment and other covariates. We compare the impact of different mod-
eling strategies and smoothness assumptions on the estimated treatment effect. Our results show that the benefits
of treatment diminish over time, possibly with implications for future treatment protocols.
Key Words: biochemical failure, MRH, multi-resolution hazard, non-proportional hazards, prostate cancer, sur-
vival analysis.
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1 Introduction
Many human cancers today are considered “chronic diseases”, with long-term disease trajectories and multiple co-
morbidities. Consequently, long-term cancer outcomes may be affected by numerous factors, ranging from obvious
patient and treatment characteristics to secular and health care trends that affect treatment policy and practice.
However, the long-term nature of patient and health-care related processes and changing complexity of information
can make the analysis of long-term patterns in cancer survivor data sets challenging. In addition to sparsely observed
failure times, these data often exhibit non-proportional effects over time, requiring flexible and computationally
efficient statistical methods to characterize the evolving failure hazard.
The motivating problem in this article comes from a set of prostate cancer clinical trials from the Radiation
Therapy Oncology Group (RTOG), which are specifically designed to examine the effects of the length of androgen
deprivation (AD) therapy on disease-free and overall survival time. As a result of the insight gained from these studies
over the years, the short-term benefits of AD therapy have been well-understood to delay the time until prostate
cancer recurrence and until death (Pilepich et al., 2001, 2005). In addition, longer-duration AD therapy has proven
more beneficial than a shorter-duration therapy (Horwitz et al., 2008). However, given that AD treatments can have
unpleasant side-effects, clinicians have been reluctant to assign androgen deprivation for longer than necessary.
Many questions remain regarding the relationship between the length of AD therapy and long-term outcomes,
such as eventual time to recurrence (Schro¨der et al., 2012). These open questions still exist in part because prostate
cancer is generally a slow cancer to progress (Albertsen et al., 2005). While prostate cancer patients tend to survive
longer and are thus observed over extended periods of time, treatment benefits have been difficult to precisely
ascertain due to a multitude of co-morbidities and sparsity of information at long follow-up times.
Thus, assessing the long-term benefits of different duration of AD therapy for patients in different risk classes
would be of great value to clinical practice and management of prostate cancer patients in general (Schro¨der et al.,
2012). Gaining insight into recurrence patterns and quantifying the degree and length of long-term benefits over
time would greatly improve the quality of life for men with this disease. For this reason, the focus of our paper
goes beyond integrated summaries such as survival curves and cumulative incidence functions, and concentrates on
estimation and inference about the time-dynamic hazard function in the presence of covariates, and the time-evolving
predictive probabilities of disease recurrence.
The underlying statistical approach employed in this paper is an extension of the multi-resolution hazard (MRH)
model, a Bayesian semi-parametric hazard rate estimator previously presented and used in Bouman et al. (2005,
2007), Dukic and Dignam (2007), Dignam et al. (2009), Chen et al. (2014), and Hagar et al. (2014a). This flexible
class of models for time-to-event data is based on the Polya tree methodology, and is also similar in spirit to the
adaptive piece-wise constant exponential models (Ibrahim et al., 2001). The MRH parametrization is designed for
multi-resolution inference capable of accommodating periods of sparse events and varying smoothness, typical in
long-term studies. In addition, the MRH model accommodates both proportional and non-proportional effects of
predictors over time. The current methodology employs the pruning algorithm presented in Chen et al. (2014), which
performs adaptive and data-driven “pre-smoothing” of the hazard rate, via merging of time intervals with similar
hazard levels. Pruning has been shown to increase computational efficiency and reduce overall uncertainty in hazard
rate estimation in the presence of periods with smooth hazard rate and low event counts (Chen et al., 2014). All
MRH models have been fitted using the ‘MRH” R package (Hagar et al., 2014b).
This paper is organized as follows. In the next section, we provide a short overview of the prostate cancer clinical
trials data, and the statistical issues related to these studies with long-term follow-up. Sections 3 and 4 present
the corresponding MRH methodology and implementation. Section 5 presents the analysis of biochemical failure
in prostate cancer, with comparisons of the MRH approach to a set of alternative models: the Cox proportional
hazards model, an extended Cox model that includes a time-varying treatment effect, a non-proportional hazards
Weibull parametric model, a semi-parametric Bayesian accelerated failure time model, a dependent Dirichlet Process
survival model, and two piece-wise exponential models. In addition we perform a sensitivity analysis to the priors in
the MRH model. The article concludes with a discussion of the clinical and statistical importance and implications
of our findings.
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2 Motivating Example: Androgen Deprivation in Prostate Cancer
Typical prostate treatment involves radiation therapy combined with some form and duration of hormone treatment,
which is known as androgen deprivation (AD) therapy. The motivation for the current analysis is the characterization
of the hazard rate of time-to-biochemical failure, adjusted for the (potentially) time-varying effects of AD therapy
and several key covariates, as described below.
The outcome of interest in this analysis, “biochemical failure”, is defined according to the Phoenix definition as
a two-unit rise in prostate specific antigen (PSA) level following a post-treatment PSA nadir (Roach et al., 2006).
Prostate specific antigen is a glycoprotein produced almost solely by prostatic epithelial cells, and is a biomarker
routinely measured to screen for possible presence of prostate cancer. Men with prostatic diseases (including cancer)
can have high serum PSA levels due to structural changes in the prostate gland as well as to the enhanced production
of PSA; therefore, elevated levels have long been used as a possible indication of the presence of prostate cancer,
including residual or recurrent disease after treatment (Cooner et al., 1990; Catalona et al., 1991; Brawer et al.,
1992). Although recent studies question PSA as a screening method for initial prostate cancer diagnoses (Barry,
2001; Thompson et al., 2004; Moyer, 2012), the examination of the rise in PSA levels post-cancer treatment is still
considered by many to be a useful clinical tool for assessing the risk or presence of prostate cancer recurrence.
The rises in PSA levels can lead to what is termed “biochemical failure”, which in itself is not currently con-
sidered a clinical endpoint. However, biochemical failure is thought to importantly portend advancing (and possi-
bly sub-clinical) disease. Prostate cancer mortality risk might also be affected by patterns in biochemical failures
(Sartor et al., 1997; D’Amico et al., 2003; Buyyounouski et al., 2008) over time. However, because of its lack of direct
clinical consequences, its use as a primary endpoint in clinical trials has been controversial.
Nonetheless, characterization of the biochemical failure hazard over time, particularly within different patient
subgroups defined by disease characteristics or treatment regimens, would provide a strong foundation for determining
how this endpoint may relate to the levels of risk for clinical recurrence and death. A better understanding of these
recurrence patterns over time could be of great value for clinical management, design of clinical trials, and biologic
insights into prostate cancer progression in different population subgroups.
The data we use to analyze biochemical failure hazard come from the Radiation Therapy Oncology Group
(RTOG), which is a national clinical cooperative group that has been funded by the National Cancer Institute
(NCI) since 1968 in an effort to increase survival and improve the quality of life for cancer patients. The group
consists of both clinical and laboratory investigators from over 360 institutions across the United States and Canada
and includes in its membership nearly 90% of all NCI-designated comprehensive and clinical cancer centers. The
specific RTOG clinical trial we examine in this paper is RTOG 92-02, which is part of a series of RTOG clinical
trials conducted from the 1980s to the present. These rich studies provide a wealth of data sources for studying the
“natural history” of prostate cancer as it is presently defined and managed clinically.
RTOG 92-02 was a multi-center study, designed with the primary objective of evaluating the effectiveness of
androgen deprivation therapy on prostate cancer disease progression and survival. Between 1992 and 1995, 1,521
participants with locally advanced high risk prostate cancer were accrued in over 200 treatment centers across the
country. During the trial, all patients received 4 months of androgen deprivation (AD) therapy including goserelin
and flutamide, in addition to external beam radiation therapy. Subjects were then randomized to either no further
AD therapy (the “+0m AD group”), or an additional 24 months of goserelin (the “+24m AD group”) using the
treatment allocation scheme described by Zelen (1974), and were stratified according to stage, pretreatment PSA,
grade, and nodal status. Given RTOG’s long history of high quality, well-randomized clinical trials with strictly
executed protocols in each institution (Radiation Therapy Oncology Group, 2014b), analyses of the pooled data
(without considering center heterogeneity) have been dominant in previous analyses of these trials (for example,
see Chakravarti et al. (2007), Che et al. (2007), Horwitz et al. (2008), and Roach et al. (2007)), and our analysis
here follows suit. Further protocol details and study description can also be found in Horwitz et al. (2008) and
Radiation Therapy Oncology Group (2014a).
For each patient enrolled, several measures of aggressiveness and severity of the original cancer were recorded at
baseline: the Gleason score, T-stage of the tumor, and the PSA level at diagnosis. The Gleason score is assigned by
a pathologist after microscopic examination of a tumor biopsy. Based on the degree to which the prostate cells have
become altered, a Gleason score ranging from 2-10 is assigned, with scores between 2 and 4 indicating almost normal
cells that pose little danger, and scores above 8 indicating very abnormal cells and a cancer that could be aggressive
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Table 1: Sample characteristics of 1,421 patients in the final RTOG 92-02 trial data set, by treatment group, with
age at diagnosis in 10-year increments, Gleason scores categorized by grade, and T-stage categorized into levels 2-4.
+0m AD +24m AD Total Sample
N % N % N %
Patients 705 49.6 716 50.4 1421 100.0
Age
Less than 60 years 44 3.1 51 3.6 95 6.7
60 to 70- years 274 19.3 260 18.3 534 37.6
70 to 80- years 363 25.5 371 26.1 734 51.7
80 or more years 24 1.7 34 2.4 58 4.1
Gleason score
Low grade (2-4) 56 3.9 47 3.3 103 7.2
Intermediate grade (5-7) 462 32.5 495 34.8 957 67.3
High grade (8-10) 187 13.2 174 12.2 361 25.4
T-stage
T2 325 22.9 331 23.3 656 46.2
T3 360 25.3 353 24.8 713 50.2
T4 20 1.4 32 2.3 52 3.7
(Epstein et al., 2005).
The American Joint Committee on Cancer (AJCC) staging criteria is used to assign the tumor a T-stage, which
indicates the extent that the primary tumor has spread. (In this analysis, we omit the ‘N’ and ‘M’ components of
AJCC staging, as they are only applicable to non-localized cancer cases). Because all patients in the RTOG 92-02
trial were selected as “high-risk” by pre-specified criteria (Radiation Therapy Oncology Group, 2014a), our data set
only contains men with tumors of stage two (T2) through four (T4). Stage T2 indicates that the tumor can be
felt during a physical examination, but has not spread outside the prostate, stage T3 indicates that the tumor has
spread throughout the prostate (or the “prostatic capsule”), and stage T4 indicates the tumor has spread beyond
the prostate (American Joint Committee on Cancer, 2014; Held-Warmkessel, 2006).
In conjunction with the Gleason score and the T-stage, PSA levels at the time of diagnosis are an important
component of prostate cancer staging, with very high levels frequently thought to be associated with a more severe
form of prostate cancer. Since the Gleason score, T-stage, and PSA level are all important components of the cancer
severity at the time of diagnosis, they, in addition to the age at diagnosis, will be considered as predictors in the
biochemical failure analysis.
The final data set considered in this analysis comprises 1,421 subjects, after the removal of 100 subjects with
missing Gleason scores. Of those 1,421 subjects, 705 men (49.6%) received no additional AD therapy (were placed
in the “+0m AD therapy” group) and 716 men (50.4%) received additional 24 months of AD therapy (the “+24m
AD therapy” group). The sample median time to biochemical failure is 4.9 years (SD = 3.9, range = 0.03 - 13.65).
Biochemical failure was observed for 50.4% of the patients before the end of the study period. The sample median
age at baseline was 70 years (SD = 6.5, range = 43-88). Table 1 summarizes the sample characteristics in more
detail.
3 Multi-resolution Hazard Model
The hazard function of the time to biochemical failure T is defined as h(t) = lim∆→0 P (t ≤ T < t+∆ | T ≥ t)/∆ =
f(t)/S(t), where S(t) = P (T > t) is the survival function and f(t) = −S′(t) is the probability density function of T .
While the hazard rate can provide a more detailed pattern over time that is not always visible in aggregate measures
such as the survival curve or cumulative hazard function, it may also be more difficult to estimate reliably. This is
particularly true if event counts are sparse, as is often the case in studies that follow subjects for extended periods
of time.
Various statistical estimators have been developed for the hazard function (Andersen et al., 1993). They vary
from classic parametric methods that assume a known family of failure time distributions such as Exponential or
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Weibull, to semi- or non-parametric smoothing methods such as those in Gray (1990, 1992, 1996), Hess (1994), and
Sargent (1997), to methods using process priors in the context of non-parametric Bayesian hazard estimation. In
this latter group, Hjort (1990) introduces the beta process prior and Lee and Kim (2004) develop a computational
algorithm to approximate a beta process by generating a sample path from a compound Poisson process. Similarly,
Kalbfleisch (1978) and Burridge (1981) model the cumulative hazard function as a gamma process. Correlated
process priors, such as those used by Arjas and Gasbarra (1994), rely on a martingale jump process to model the
hazard rate. In Nieto-Barajas and Walker (2002), the prior correlation is introduced via a latent Poisson process
between two adjacent hazard increments. Other non-parametric Bayes hazard rate estimation methods are reviewed
in Sinha and Dey (1997) and Mu¨ller and Rodriguez (2013).
Different predictors and covariates can be included in hazard modeling under the proportional hazards assumption
(Cox, 1972; Ibrahim et al., 2001; Bouman et al., 2007). However, with longer-term follow-up, the assumption of
constant proportionality between the hazard rates for different patient subgroups may be questionable, either because
the effects change throughout the course of a study, or because the remaining patients constitute a subpopulation
significantly distinct from the population at baseline. In these instances, it is important to relax the proportionality
of hazards assumption over time.
One of the simplest ways to accommodate non-proportionality of hazard functions among groups of patients is
to perform a stratified analysis and estimate each group’s hazard function separately. However, this simple method
cannot jointly estimate the hazard rates and effects of predictors, nor allow for correct quantification of uncertainty.
More sophisticated investigations involve the use of piece-wise hazard functions, examples of which can be found
in Holford (1976, 1980), Laird and Olivier (1981), and Taulbee (1979). Other methods address non-proportionality
issues by pre-testing and comparison of two survival or hazard functions through graphics and asymptotic confidence
bands (Dabrowska et al., 1989; Parzen et al., 1997; McKeague and Zhao, 2002), or through asymptotic confidence
bands for changes in the predictor effects over time (Wei and Schaubel, 2008; Dong and Matthews, 2012). Some of
these methods mentioned require large sample sizes for inference, and their performance can degrade over time in
studies with sparser outcomes in later periods. Alternative approaches to handling non-proportionality have been
implemented through accelerated failure time (AFT) models (with initial work done by Buckley and James (1979)
and a thorough review found in Kalbfleisch and Prentice (2002)), which accommodate non-proportionality through
specific parameterization of the time to survival and the covariates. As a result, these models can only accommodate
certain types of non-proportionality, such as non-proportional hazards that do not cross.
In the Bayesian context, non-proportionality has been addressed in a number of ways; Berry et al. (2004) es-
timate piece-wise constant hazard rates for each of the treatment groups, and Nieto-Barajas (2014) extends a fre-
quentist model by Yang and Prentice (2005) that estimates short and long term hazard ratios for crossing hazards.
Hennerfeind et al. (2006) have developed a survival model that incorporates functions for time-varying covariate
effects into the hazard rate using Bayesian P-spline priors, while Cai and Meyer (2011) develop a Bayesian stratified
proportional hazards model using a mixture of B-splines. Further, De Iorio et al. (2009) use a dependent Dirichlet
Process (DDP) to non-parametrically estimate non-proportional hazards. We compare and discuss many of these
models in Section 4.2.
The MRH model is closely related to the Polya tree (Ferguson, 1974; Lavine, 1992). The Polya-tree prior is an
infinite, recursive, dyadic partitioning of a measurable space Ω. (Although in practice this process is terminated
at a finite level M , resulting in “finite” Polya trees.) Polya trees have been adapted for modeling survival data
in a number of ways (for example, see Muliere and Walker (1997); Hanson and Johnson (2002); Hanson (2006);
Zhao et al. (2009)). A stratified Polya tree prior is developed by Zhao and Hanson (2011), with the tree centered at
the log-logistic parametric family. The “bins” of the Polya tree are fused together in the “optional Polya tree” (OPT),
developed by Wong and Ma (2010), with fusing performed through randomized partitioning of the measurable space
and a variable that allows for the stopping of the partitioning in different subregions of the tree. The “rubbery
Polya tree” (rPT), developed by Nieto-Barajas and Mu¨ller (2012), smooths the partitioned subsets by allowing the
branching probabilities to be dependent within the same level, implemented through a latent binomial random
variable.
The MRH prior is a type of Polya tree; it uses a fixed, pre-specified partition, and controls the hazard level within
each bin through a multi-resolution parameterization. This parameterization allows parameters to differ across bins
and levels of the tree in such a way that the marginal priors at higher levels of the tree are the same, regardless
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of the priors at lower levels of the tree. The MRH model is capable of producing group-specific non-proportional
hazards estimates (in the presence of proportional hazards covariates), allows for a data-driven fusing of bins (called
“pruning”), and includes parameters that can control the smoothness and correlation between intervals.
3.1 MRH Methodology for Mon-proportional Hazards (NPMRH)
The basic MRH was extended in Dukic and Dignam (2007) into the hierarchical multi-resolution (HMRH) hazard
model, capable of modeling non-proportional hazard rates in different subgroups jointly with other proportional
predictor effects. Like HMRH, the methodology in this paper allows for group-specific hazard functions, but adds
the pruning methodology of Chen et al. (2014) for individual hazard rates. The pruning algorithm detects consecutive
time intervals where failure patterns are statistically similar, increasing estimator efficiency and reducing computing
time. The resulting method produces computationally stable and efficient inference, even in periods with sparse
numbers of failures, as may be the case in studies with long follow-up periods (Chen et al., 2014). Details of the
MRH prior and the pruning method are found in Appendix A.
3.1.1 NPMRH Likelihood Function
The biochemical failure time data is subject to right-censoring: a patient’s biochemical failure time is considered
right-censored if it has not been observed before the end of the study period (time tJ), or the censoring time (tcens,
where tcens < tJ). We denote Ti as the minimum of the observed time to biochemical failure or the right-censoring
time for subject i. Each patient belongs to one of the L covariate (for example a combination of treatments) strata,
and within each stratum we employ the proportional hazards assumption such that:
hℓ(t | X, ~β) = hbase,ℓ(t) exp{X
′~β}.
Here, hℓ denotes the baseline hazard rate for treatment strata ℓ, X represents the z × nℓ matrix of z covariates
(other than those used for stratification) for the nℓ patients in the stratum ℓ, while ~β denotes the z× 1 vector of the
covariate effects.
For subject i in stratum ℓ who has an observed failure time at Ti,ℓ ∈ [0, tJ), the likelihood contribution is:
Li,ℓ(Ti,ℓ | Xi,ℓ, ~β) = hbase,ℓ(Ti,ℓ) exp(X
′
i,ℓ
~β)Sbase,ℓ(Ti,ℓ)
exp(X′i,ℓ
~β),
where Xi,ℓ is that subject’s covariate vector, and Sbase,ℓ is the baseline survival function for the stratum ℓ. Similarly,
for a subject in stratum ℓ whose failure time is greater than the censoring time, the likelihood contribution is:
Li,ℓ(Ti,ℓ | Xi,ℓ, ~β) = Sbase,ℓ(Ti,ℓ)
exp(X′i,ℓ
~β).
Thus, the likelihood for all n patients in all L strata together (n =
∑L
ℓ=1 nℓ) is
L(T | β˜,H,Rm,p,X) =
L∏
ℓ=1
∏
i∈Sℓ
[
hbase,ℓ(Ti,ℓ)e
X′i,ℓ
~β
]δi,ℓ
Sbase,ℓ(Ti,ℓ)
e
X′
i,ℓ
~β
,
where Sℓ denotes the set of indices for subjects belonging to the stratum ℓ, and δi,ℓ = 1 if subject i had observed
biochemical failure, and 0 if censored. In this model, the L hazard rates are estimated jointly with all the covariate
effects. The estimation algorithm is performed two steps: the pruning step and the Gibbs sampler routine. Details
are provided in Appendix B.
3.1.2 Inference for Non-proportional Effects
A non-proportional covariate effect can be described as the log of the hazard ratio between different covariate strata
in each bin. For simplicity, let us assume that the model has only one non-proportional effect predictor with ℓ
categories – for example, ℓ treatment groups. Let αℓ,ℓ+1(t) denote the hazard effect of treatment group ℓ + 1 with
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respect to treatment group ℓ. Then αℓ,ℓ+1(t) can be thought of as a time-varying effect, which is constant within
each time bin, but changes across time bins. In other words,
αℓ,ℓ+1(t) =
[
αℓ,ℓ+1(t1 − t0), . . . , αℓ,ℓ+1(tJ − tJ−1)
]′
= log
([
d1,ℓ+1/d1,ℓ, . . . , dJ,ℓ+1/dJ,ℓ
]′)
,
where dj,ℓ, j = 1, . . . , J, ℓ = 1, . . . ,L represents the hazard increment in the jth bin of the ℓth strata, and is defined as
dj =
∫ tj
tj−1
h(s)ds = H(tj)−H(tj−1) (see Appendix A for details). For the biochemical failure model, the time-varying
effect of treatment is thus:
α0,1(t) = log
([
d1,1/d1,0, . . . , dJ,1/dJ,0
]′)
,
where 0 represents the short-term androgen deprivation therapy group, and 1 represents the long-term androgen
deprivation therapy group. The marginal posterior distribution of this time-varying effect of treatment can therefore
be obtained directly from the joint posterior distribution for the hazard increments d.
4 Analysis of RTOG Prostate Cancer Clinical Trial Data
The main goal of our analyses of the time biochemical failure was to infer how the effects of AD therapy impacted
the failure time, and if and how they may have changed over the course of treatment and the subsequent 10 year
post-diagnosis follow-up. Of particular interest was to assess whether the benefit of longer over shorter duration
androgen deprivation (AD) therapy was persistent over time or if it diminished in the late follow-up. Additionally
of interest was whether the biochemical failure hazard rate for the long-duration AD (+24m) group increased later
in follow-up, indicating that failures were deferred in time rather than avoided. Inference in the later time periods
is more challenging however, as the RTOG 92-02 clinical trial exhibits sparsity of events towards the end of the
follow-up time as is typical of long-term studies. Fewer observed biochemical failures occurred in the later periods,
with only 13% of the subjects having observed biochemical failure after 4.9 years (the median time to biochemical
failure), and only 1.5% after 10 years.
Several previous studies have used time aggregated summaries (i.e., survival curves, cumulative incidence) to
estimate cumulative biochemical failure risk over time (Nguyen et al., 2013; Taira et al., 2013). However, previous
analyses specifically examining the hazard rate of biochemical failure are relatively scarce. These analyses have been
limited to the clinical literature and used intuitive summaries to approximate the annual hazard, for example, by
calculating the annual number of events divided by the number at risk (Amling et al., 2000; Dillioglugil et al., 1997;
Hanlon and Hanks, 2000; Walz et al., 2008). These analyses provide basic, useful information on the patterns of
hazard of biochemical failure over time, and have helped identify higher and lower periods of hazard for specific
patient groups. However, the straightforward methods used do not provide smoothed estimates of the hazard rate
over time, and the joint estimation of the effects of multiple covariates on hazards was not considered. In addition,
during periods of time when no biochemical failures were observed, these estimation procedures calculated the hazard
rate to be zero.
Thus, the analyses here investigate the effects of treatment, age, Gleason scores, PSA levels, and T-stage at diag-
nosis on the time to biochemical failure, allowing for possible non-proportional treatment effects. In order to provide
a thorough investigation of the treatment hazard ratio over time and to determine the effects of different modeling
and smoothness assumptions on the estimate, we present a suite of models ranging from simple parametric models
to more complex non-parametric models. In addition to the standard and pruned MRH models, we also employ a
parametric non-proportional hazards Weibull model, two piece-wise exponential models (Zelen, 1974; Ibrahim et al.,
2001), an extended Cox model that allows for time-varying covariate effects (Martinussen and Scheike, 2006), a
Dependent Dirichlet Process survival model (De Iorio et al., 2009), and a semi-parametric Bayesian accelerated fail-
ure time model (Koma´rek and Lesaffre, 2007). All MRH models were implemented using the “MRH” R package
(Hagar et al., 2014b).
The following covariates were examined in the models:
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• Treatment (+0m vs +24m AD therapy)
• Age (categorized: less than 60 years, 60 to 70- years, 70 to 80- years, and 80 years or older)
• Gleason scores (categorized: low grade, intermediate grade, and high grade, corresponding to scores between
2-4, 5-7, and 8-10, respectively)
• PSA levels (log transformed and then centered at the mean log value equal to 3)
• T-stage (binary: stage 2, or stage 3/4)
The baseline (reference) group comprises subjects who received no additional androgen deprivation therapy (+0m),
had an intermediate Gleason score, were below age 60 at study entry, and had a T-stage equal to 2.
4.1 MRH Results
The time resolution M = 6 was chosen for this analysis in order to provide a fine grain examination of biochemical
failure patterns over the course of more than 13 years. The resulting J = 64 time intervals, partitioning the time axis
into bins of length 2.5 months, allowed us to investigate detail in the biochemical failure hazard rate that is useful
to clinical practice. The full 64-bin MRH model with non-proportional treatment hazards (the “NPMRH-0” model)
was compared to two pruned MRH models with non-proportional treatment hazard rates, one with all 6 levels of the
MRH tree pruned (“NPMRH-6”), and one with only the bottom 3 levels of the MRH tree pruned (“NPMRH-3”).
Pruning the 64-bin model allowed us to fuse bins where the failure rates were statistically similar (reducing the
number of model parameters), which in turn helped us identify periods of time where the hazard rates were flat and
where treatment effects remained steady. To test whether the non-proportionality of hazards was indeed warranted
in the model, we also examined a pruned MRH model (a 6-level model with the bottom 3 levels subject to pruning)
with the treatment effect included under the proportional hazards assumption (PHMRH).
Five separate Markov chain Monte Carlo (MCMC) chains were run for each model, each with the burn-in
of 50,000, leaving a total of 150,000 thinned iterations in each chain for analysis. Convergence was determined
through the Geweke diagnostic (Geweke, 1992), graphical diagnostics, and Gelman-Rubin tests (Gelman and Rubin,
1992; Brooks and Gelman, 1998). These diagnostics are automatically presented when using the MRH R package
(Hagar et al., 2014b). Point estimates for the MRH models were calculated as the median of the marginal posterior
distribution of each parameter. Central credible intervals were used for inference.
One of the most notable features of our results are in the estimated log-ratio of the treatment effect, particularly
in the pruned models. In examining Figure 1, we note the interval-specific differences displayed in the caterpillar
plots (top 3 plots in Figure 1). These plots reveal several important pieces of information about the treatment effects,
including time periods where the treatment effects were: 1) proportional (constant) or non-proportional (changing),
2) statistically significantly different from previous periods, and 3) statistically significantly different from zero or
from the proportional hazards model estimate of the treatment effect. For example, in the NPMRH-3 model, the
treatment effects remained steady between (approximately): 6 ms-2 years, 3.5-4 years, 5-6.5 years, 6.5-8 years,
and 8-10 years. However, these periods of constant estimated treatment effects were different from one another,
suggesting that while the benefits of treatment lasted for a certain number of years, the degree of improvement
changed (and generally declined) over the course of the study. Between 6 months and 2 years, long-term AD therapy
had an estimated 75% improvement over short term AD therapy. In examining the 95% bounds of the boxplots, this
estimated log-hazard ratio is statistically different than the log-ratio estimate from the proportional hazards model
of β̂tx = −0.597 (which translates to 45% improvement for the +24m group). Additionally, the estimated log-ratio
in this time period is statistically significantly different than the estimated treatment effects between 5-6.5 and 8-10
years, which only showed an estimated 26% improvement for subjects on long-term therapy (see Figure 2, bottom).
In both pruned models, the treatment effect held steady for a certain number of years, then diminished slightly, and
held steady for another number of years, before diminishing in effectiveness again. Overall, long-term AD therapy
did better in prolonging time to biochemical failure throughout most of the first 10 years of the study, despite the
fact that in certain periods the log-ratio is not statistically significantly different from zero.
The results of all the MRH models provide two important insights: 1) The proportional hazards assumption
indeed did not hold for treatment effects (agreeing with the Cox model test), and there were in fact periods of time
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Figure 1: Comparison of parameter estimates produced by the different MRHmodels. TOP: Caterpillar plots of the treatment log-hazard
ratio for the three non-proportional MRH models with different levels of pruning. The model on the top has no pruning (NPMRH-0),
and shows the most variation between and within bins. As the level of pruning increases (NPMRH-3 and NPMRH-6), the uncertainty of
the estimates decreases. In addition, the pruned models communicate the patterns in the log-hazard ratio more clearly: larger treatment
differences are visible at the beginning and end of the study, with long periods of stability in the middle. All caterpillar plots have
two reference horizontal lines: the grey line crosses the y-axis at 0, and the blue line at -0.597 (the estimate of the treatment effects
under the proportional hazards using the the PHMRH model). BOTTOM LEFT: Covariate effect estimates and corresponding credible
bounds for the MRH and NPMRH models. The figure shows that the estimated covariate effects are very similar among all models,
regardless of the level of pruning or the treatment effect proportionality assumption. BOTTOM RIGHT: The smoothed log hazard ratio
of the long-duration AD (+24m) group to the short-duration (+0m) group for NPMRH-0, NPMRH-3, and NPMRH-6 models, contrasted
against the estimate of treatment effect under the proportional hazards assumption (obtained from PHMRH). The solid lines represent
the log-hazard ratio estimate, and the dashed lines represent the smoothed point-wise 95% credible intervals. The hazard rate estimates
are very similar among the three models. However, the two models that have pruned trees have narrower credible intervals, as they have
a smaller number of estimated parameters. Note that in all models, the credible bands become large towards the end of the study, due to
the decreasing frequency of observed biochemical failures as time progresses. However, the pruned models show lower variability towards
the end of the study period, as the per-bin observed failure count is higher in those models.
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Coefficient β̂ ĤR 95% CI for β
Gleason score 2-4 -0.11 0.90 (-0.43, 0.18)
8-10 0.30 1.35 (0.13, 0.46)
Age 60− 70
− -0.12 0.88 (-0.39, 0.16)
70− 80− -0.44 0.64 (-0.71, -0.16)
80 or older -0.07 0.94 (-0.52, 0.37)
T-stage 3 or 4 0.14 1.15 (-0.01, 0.29)
log(PSA), centered 0.29 1.34 (0.21, 0.37)
Table 2: Estimated covariate effects for the NPMRH-3 model. Baseline subjects are those who have a Gleason score between 5 and 7,
are less than 60 years of age, and have a T-stage equal to 2. The β̂ column contains the estimates of the log of the hazard ratios, and the
ĤR column contains the coresponding estimated hazard ratios. Model estimates for all the different MRH (with and without pruning)
are very similar, as can also be observed in Figure 1.
where the estimated effects are statistically significantly different from each other, and 2) On average, the subjects
on +24m of AD therapy experienced benefits for at least 10 years post treatment.
In Figure 1 (bottom right), we present the smoothed version of the caterpillar plots above, illustrating the overlap
of the credible regions around the estimated log-hazard ratio for the four different models. The smoothing was done
using a cubic smoothing spline (with 5 degrees of freedom, 53 knots, and a smoothing parameter equal to 0.82),
which was implemented via the smooth.spline() function in R. While the caterpillar plots are useful for identifying
specific interval differences in the treatment effect, these smoothed plots emphasize the difference in the uncertainty
among the models and the different shapes of both the estimated effects and their credible intervals. For example, we
see that among the NPMRH models, the unpruned model (NPMRH-0) has the widest credible interval bands, while
the fully pruned model (NPMRH-6) has the narrowest credible interval bands, which is due to the smaller number
of estimated parameters and larger failure counts per bin in the pruned model. While the PHMRH model clearly
has the narrowest credible region, the constant parameter estimate cannot identify periods of increased or decreased
long-term treatment benefit. This discrepancy is particularly visible in the last third of the study, where the benefits
of long-term treatment seem to be decreasing.
The estimates and their 95% credible intervals for the time-invariant effects (effects of age, Gleason scores, PSA
measures, and T-stage) are almost identical among all the MRH models, and are shown in the “cat-scratch” plot in
Figure 1, bottom left.
In all models, estimates of the biochemical failure hazard rate for each treatment group showed an increase in the
first two to four years, with a steady decline afterwards (see Figure 2, upper left). However, subjects who received 24
months of additional AD therapy had a lower hazard rate than those who did not, with a flatter peak between 2 and
4 years. The non-proportionality between the hazards is particularly visible when compared to the results from the
proportional hazards model. While both the NPMRH-3 and PHMRH models show similar estimated hazard rates
for the +0m AD therapy group, the estimated hazard rates for the +24m group had significant departures in the
first four to five years of the study, as well as in the last two years of the study. It does appear that, while long-term
treatment effects diminished over time, biochemical failure was not simply postponed for the +24m group, but the
risk was in fact reduced even over a longer period of time.
Time-invariant effect estimates show that an increase in Gleason scores was associated with an increased hazard
rate, with a statistically significant difference between baseline subjects and subjects with scores greater than 8 (HR
= 1.35, 95% CI: 1.14, 1.59). The hazard of biochemical failure decreased with age, although significant differences
were only observed for subjects between 70 and 80 years old and baseline subjects (HR = 0.64, 95% CI: 0.49, 0.86).
As expected, subjects with a T-stage of 3 or 4 had a higher hazard of biochemical failure compared to subjects with
a T-stage equal to 2 (HR = 1.15 , 95% CI: 0.99, 1.34). Similarly, for every point increase in PSA scores on the log
scale (a 2.7 factor increase in PSA measures on the standard PSA scale), there was a statistically significant 34%
increase in the hazard rate. (See Table 2, Figure 1 bottom left.)
The probability of biochemical failure at 1, 5, and 10 years can be observed in Figure 3, which shows the smooth
posterior predictive probability densities of biochemical failure, stratified by treatment type for hypothetical subjects
with a“worst” or “best” covariate profile. A subject with a “worst” profile had a Gleason score ≥ 8, a T-stage 3 or 4
tumor, and a PSA score equal to 1 standard deviation greater than the mean (PSA ≈ 52). A subject with a “best”
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Figure 2: TOP LEFT: Smoothed estimated hazard rates (baseline subjects only) for the +24m AD therapy group (red) compared to
the +0m AD therapy group (black). The hazard rates estimated under the non-proportional assumption are represented with solid lines,
and the hazard rates estimated under the proportional assumption are represented with dashed lines (calculating the +24m hazard rate
at time t as h0(t) exp{βtx}). While the estimated hazard rate for the +0m AD therapy group is similar under both the proportional
and non-proportional modeling assumptions, the +24m hazard rate estimates have larger departures, with a flatter 2-year peak for the
estimate from the non-proportional hazards model. TOP RIGHT: Smoothed estimated hazard rates (baseline subjects only) and 95%
credible interval bounds for the +24m AD therapy group (red) compared to the +0m AD therapy group (black). The intervals are
slightly narrower for the +24m treatment group when compared to the +0m treatment group, although the credible intervals for the
+24m estimated hazard rate become wider at the tail end of the end of the study where few failures are observed. BOTTOM: A caterpillar
plot of the effects of long-term vs short-term treatment over time. The grey line lies on the y-axis at 0, and the blue line lies on the y-axis
at -0.597, which is the estimate of the treatment effect under the proportional hazards setting (estimate from the PHMRH model). It
is particularly apparent at the beginning of the study that the proportional hazard rate estimate for treatment is not contained in the
boxplot bounds. In addition, we can see that the boxplot medians have a lot of variation, and even change from negative to positive
multiple times throughout the course of the study. All estimates shown are from the NPMRH-3 model.
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Figure 3: Smoothed posterior predictive densities of biochemical failure at 1, 5 and 10 years post-diagnosis, stratified by treatment type
and hypothetical patient covariate profile. A subject with a “worst” profile had a Gleason score ≥ 8, a T-stage equal to 3 or 4, and a
PSA score equal to 1 standard deviation greater than the mean (PSA ≈ 52). A subject with a “best” profile had a Gleason score ≤ 4, a
T-stage equal to 2, and a PSA score equal to 1 standard deviation below the mean (PSA ≈ 8). At one year post-diagnosis, the predictive
densities of biochemical failure were very similar for all groups. However, at 5 and 10 years the densities became more spread out. A
worst profile subject on +0m of AD therapy had the highest predictive probability of biochemical failure, while a best profile subject on
+24m AD therapy had the lowest predictive probability of biochemical failure. While all densities overlapped at one year, at 5 and 10
years very little overlap remained between the best and worst profile within the same treatment regimen. In addition, at all three time
points, the predictive probability of biochemical failure was higher for the worst profile subjects (regardless of treatment) than the best
profile subjects. Smoothed density estimates were calculated using density() in R.
profile had a Gleason score ≤ 4, a T-stage equal to 2, and a PSA score equal to 1 standard deviation below the mean
(PSA ≈ 8). At one year post diagnosis, we see that the posterior predictive densities were very similar among the
four groups, all concentrated between 0 and 20%. However, by the 5-year post-diagnosis mark, the failure densities
were very different. A worst profile subject on +0m AD therapy had failure probability centering around 80%, while
a best profile subject on +24m of AD therapy had failure probability centering around 20%. It can also be observed
that a worst profile subject had higher failure probability than a best profile subject, regardless of treatment type.
The failure probability at 10 years post-diagnosis is perhaps the most telling, with a worst profile subject on +0m
AD therapy having a failure probability ranging from 80-100%, which is a narrower range when compared to the
other groups. Meanwhile, a best profile subject on +24m therapy had failure rates centering around 40%, over a
wider interval from approximately 20% to 60%. While all posterior predictive densities overlapped at one year, at 5
and 10 years there was only a small amount of overlap between the best and worst profile subjects within the same
treatment regimen.
4.2 Model Checking and Comparison
To assess the impact of different modeling and smoothness assumptions on the hazard of time to biochemical failure,
we compared the four MRH models to each other as well as to other models, including the Cox proportional hazards
model, a parametric non-proportional hazards Weibull model, two piece-wise exponential (PE) models, a dependent
Dirichlet Process (DDP) survival model, and a semi-parametric Bayesian accelerated failure time (AFT) model,
allowing for time-varying treatment effects in all models. In addition, we performed a sensitivity analysis to the
parameter k, which controls the smoothness in the MRH tree prior (Bouman et al. (2005), see Appendix A for
details). When applicable, models were compared through a goodness-of-fit measure (defined in Section 4.2.3), as
well as via information criteria including BIC (Schwarz, 1978), AIC (Akaike, 1974), and DIC (Spiegelhalter et al.,
2002; Celeux et al., 2006).
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Figure 4: Schoenfeld residuals for the treatment effect,
with a weighted least squares line. Deviation from linearity
indicates that the treatment effect does not fit the propor-
tional hazards assumption.
Cox Proportional Hazards Model
Because the Cox proportional hazards model is widely used in the analysis of survival data, we included this model
as a comparison to other non-proportional hazards model for contrast (Cox, 1972). While we modeled the treatment
effect under the proportional hazards assumption, it is important to note that the Schoenfeld residuals and methods
presented by Grambsch and Therneau (1994) showed evidence that the treatment effect (long-term versus short-term
therapy) was not proportional over the entire study period (see Figure 4). No other covariate effects showed evidence
of non-proportionality over time.
Cox Model Extension
In addition to the traditional Cox proportional hazards model, we included an extended proportional hazards model
with a time-varying treatment effect (Martinussen and Scheike, 2006). This extended Cox model has a hazard rate
with the form
λ(t) = Y (t)λ0(t) exp{X
T (t)β(t) + ZT (t)γ}, (1)
where (X(t), Z(t)) is a (p + q)-dimensional covariate, β(t) = (β1(t), ..., βp(t)) is a p−dimensional time-varying (i.e.
NPH) regression coefficient that is estimated non-parametrically, and γ is the q-dimensional regression parameter
for the PH covariate effects. An implementation of this model was performed using the timecox() function in the
“timereg” package (Scheike, 2014), where parameters are estimated using score equations, and the optimal smoothing
parameter was chosen based on the lowest -2*log-likelihood value and the lowest GOF scores.
Accelerated Failure Time Model
Accelerated failure time models are an alternative way to investigate the effects of non-proportional hazards. In our
analysis, we used a Bayesian AFT model (Koma´rek and Lesaffre, 2007). This model can accommodate more complex
clustered, interval-censored survival data, with the log of the survival times is modeled as:
log(Ti,l) = β
′xi,l + b
′
izi,l + ǫi,l, i = 1, . . . , N, l = 1, . . . , ni,
where Ti,l is the event time of the l
th observation of the ith cluster. The model estimates the effects, β = (β1, . . . , βp),
of the fixed effects xi,l and the i.i.d random effects bi = (bi,1, . . . , bi,q)
T . The fixed and random covariate effects are
modeled using the classical Bayesian linear mixed model approach (such as Gelman et al. (2004)), and the hazard
rate is approximated by normal mixtures. For the purposes of the prostate data, we omit any clustering effects.
Dependent Dirichlet Process Survival Model
As the most flexible alternative, we also consider a non-parametric Bayesian model that can accommodate non-
proportional hazards. This model is based on the ANOVA Dependent Dirichlet Process (DDP) model presented
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in De Iorio et al. (2004), that has been extended to the survival analysis setting (De Iorio et al., 2009). The DDP
survival model performs survival regression based on a Dirichlet Process prior.
The set of the random probability distributions or functions are dependent in an ANOVA-type fashion: If {Fx, x ∈
X} is the set of random distributions indexed by the categorical covariates x = (x1, . . . , xp), and the collection of
random distributions is defined as
Fx =
∞∑
h=1
phδ(θxh), for each x ∈ X,
with
∑∞
h=1 ph = 1, and δ(y) representing a point mass at y, then dependence is introduced by modeling the locations
θxh through the covariates (as explained in De Iorio et al. (2004) and De Iorio et al. (2009)). This model allows
all group-specific hazards to be modeled non-proportionally, and covariate effects are interpreted in the standard
ANOVA manner. The model is also capable of accommodating continuous covariates.
Because of the greater flexibility with the DDP survival model, this model is often unable to estimate all desired
covariate effects. As a result, we present this model on a reduced set of variables that were found to be significant
in other models: treatment, a high Gleason score, age between 70 and 80 years, and log(PSA).
Non-Proportional Hazards Weibull Model
The non-proportional effects Weibull model was designed with separate Weibull hazard rates for each treatment
group and proportional hazard covariate effects shared among both treatment groups. Parameter estimates for this
model were obtained using numerical optimization of the likelihood function:
L =
2∏
ℓ=1
[ ∏
i∈txℓ
(
κℓλℓ (λℓTi,ℓ)
κℓ−1 exp
{
X ′i,ℓ
~β
})δi,ℓ
exp
{
−(λℓTi,ℓ)
κℓ exp
{
X ′i,ℓ
~β
}}]
,
where ~β are the covariate effects modeled under the proportional hazards assumption. The estimate of the log-hazard
ratio of the non-proportional effect of treatment at time t > 0 in the Weibull model was then obtained as
αW (t) = log
(
κ1λ1 (λ1t)
κ1−1
κ0λ0 (λ0t)
κ0−1
)
,
where group 0 is the short-term treatment group, and group 1 is the long-term treatment group. The non-proportional
hazardsWeibull model parameter estimation was not performed using any available software packages, but is available
on request from the authors.
Piece-wise Exponential Models
The piece-wise exponential (PE) model is a commonly used frequentist semi-parametric model for joint estimation
of the hazard rate and covariate effects (for example, see Friedman (1982)). It is similar to the MRH model in that
both assume constant hazard rates within a time bin j (j = 1, . . . , J), but it does not have the multi-resolution
aspects of MRH.
As with the non-proportional hazards Weibull model, we fit a PE model with separate hazard rates for each
treatment group, and shared proportional hazards effects among all subjects. If we let λj,ℓ represent the constant
hazard rate in the jth bin for the ℓth treatment group (j = 1, . . . , J, and ℓ = 1, 2), then the piece-wise exponential
likelihood can be written as:
L(T | β˜,X, δ, λ) =
n∏
i=1
2∏
ℓ=1
J∏
j=1
(
λj,ℓ exp{X
′
i
~β}
)δij,ℓ
exp
{
−ωij,ℓλj,ℓ exp{X
′
i
~β}
}
,
where
δij,ℓ =
{
1 if subject i is in treatment group ℓ and has a failure in time bin j
0 otherwise,
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ωij,ℓ =
{
tj,ℓ − tj−1,ℓ if subject i is in treatment group ℓ and Ti,ℓ > tj , ℓ
T i− tj−1,ℓ if subject i is in treatment group ℓ and Ti,ℓ ∈ [tj−1,ℓ, tj,ℓ]
0 otherwise.
To make the PE model comparable with the pruned MRH models, we use a data-driven method to select the
optimal number of bins J, as well as the optimal bin width(s). In addition, we modify the standard PE approach
slightly in order to overcome a common obstacle in the estimation of the variance. Namely, given that the Fisher
Information for the hazard rate in bin j for group ℓ can be derived as:
I(λj,ℓ) = −
∑n
i=1 δij,ℓ
λ2j,ℓ
,
bins with no observed failures will yield I(λj,ℓ) of zero, making the Fisher Information matrix singular. In such
instances, we have remedied this issue by (repeated) merging of the bins with no observed failures into the adjacent
bins to the left. With that modification, for each of the hazard rates, we find the PE model with the optimal number
of bins and bin widths based on an information criterion such as AIC (Akaike, 1974), in two ways:
1. Equal-bin model: The “equal-bin” PE model partitions the time axis evenly into j bins (where j = 2, . . . , J).
Among the J − 1 equal-bin PE models, we retain the model that has the lowest AIC value.
2. Quantile-bin model: The “quantile-bin” PE model partitions the time axis into j quantiles (j = 2, . . . , J).
Among the J − 1 quantile-bin PE models, we retain the model that has the lowest AIC value.
In the RTOG 92-02 data set, the final equal-bin PE model had 17 bins for the +0m treatment group hazard rate
and 18 bins for the +24m treatment group hazard rate. The last three bins were combined for the +0m treatment
group, and the last two bins had to be combined for the +24m treatment group hazard rate. (Note that as the
result, not all bins were of equal length due to the combined bins at the end of the study). The final quantile-bin
model had 24 bins for the +0m treatment group hazard rate and 25 bins for the +24m treatment group hazard rate.
The last three bins were combined for the +0m treatment group, and the last two bins were combined for the +24m
treatment group.
4.2.1 Comparison of Estimated Hazard Ratio and Predictor Effects
The estimates from all models are compared visually in Figures 6 and 5. All models were remarkably similar in terms
of the proportional hazard covariate effects, both in point estimates and their 95% bounds (credible intervals for the
MRH model, and confidence intervals for the remaining models), as can be seen in Figure 5. Given this similarity,
we refer the readers to Table 2 and Section 4.1 for interpretation and discussion of these effects in the NPMRH-3
model. (Note that the estimated covariate effects for the AFT and DDP survival models are not shown as their
number and interpretation are different than the other models.)
In contrast, the estimates of the time-varying treatment effect show notable differences (Figure 6). The PE and
MRH models provide similar estimates, although the PE model log-HR estimates exhibit a rapid increase towards
the end of the study when the number of observed failures becomes sparse (top right graph). Due to its parametric
form, the NPH Weibull model has an initial dip in the estimated treatment effect, and then slowly but steadily
increases over the course of the study, although the estimated effects remain negative throughout the study period.
The extended Cox model shows a similar pattern and estimate, without the initial dip (top left graph). The AFT
estimated log-HR follows a trajectory similar to that of the NPH Weibull model, including the wider 95% confidence
interval bounds in the initial study period (bottom left graph). The DDP survival model (calculated on the subset
of significant predictors only) shows an initial pattern similar to that of the NPMRH-3 model (also calculated on
the subset of significant predictors only), with a dip at the two year mark, followed by an upward trend. The DDP
survival model is the only model that shows a possible decreasing trend towards the end of the study. For comparison,
the Cox PH model treatment estimate (included under the proportional hazards assumption), has been included in
all graphs as a constant value over time (βˆ = −0.59, 95% CI: -0.74, -0.44). It can be observed that throughout
various periods of the study, all models have estimated treatment effects that extend outside the 95% confidence
interval for the Cox PH model treatment effect. In addition, all models show that long-term treatment is beneficial
over longer periods of time, even if the effects may be diminishing.
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Figure 5: The estimates for the proportional hazards covariate effects and corresponding 95% intervals (credible intervals for NPMRH-3,
confidence intervals for the remaining models). Differences are minor, even among the widths of the 95% intervals, between the different
models. The AFT and DDP survival model estimates are not included as their number and interpretation is different than the standard
Cox PH covariate interpretation.
4.2.2 Sensitivity Analysis to Parameter k in the MRH Models
In all the MRH models, the parameter k controls the correlation among the hazard increments within each bin
(Bouman et al. (2005), see Appendix A for details). The default value for k in the above analyses was 0.5, which
implies zero a priori correlation among the hazard increments. However, when k > 0.5, the increments are positively
correlated a priori, and, similarly, when k < 0.5, the hazard increments are negatively correlated a priori. Another
way to understand the impact of k is that higher values lead to smoother hazard functions.
In practice, different approaches to choosing a hyperprior for k, including empirical Bayes methods, are possible.
However, k will in general tend to depend on the resolution level (Bouman et al., 2005), as well as with the significance
level used in the pruning algorithm (Chen et al., 2014). Both the resolution and the pruning can be also used to
imply the desired a priori level of smoothness of the hazard function. For this reason, we fix k in the above analyses,
and perform a sensitivity analysis to examine the effect the choice of k might have on the posterior hazard rate
estimates. We only examine the effects of different values of k in the 3-level pruned MRH model (NPMRH-3) (see
Subsection 4.2.3 for motivation.)
The sensitivity analysis results are displayed in Figure 7. On the left plot in Figure 7, the original NPMRH-3
model (with k = 0.5) is contrasted against the models with negatively correlated hazard increments (k = 0.2), and
positively correlated hazard increments (k = 1.0). As anticipated, in the negatively correlated model the log-HR
is less smooth, and has wider 95% credible intervals, resembling the PE model results. However, the NPMRH-3
model with k = 1.0 is smoother, with narrower 95% credible intervals. The positive correlation between hazard
increments results in smoother posterior estimates, as more information is shared across bins. The right graph of
Figure 7 highlights the adaptability of the MRH model in controlling the smoothness of the log-hazard ratio through
the parameter k. In this instance, with k fixed at a very high value of 10 (highly positively correlated increments),
the NPMRH-3 model closely mimics the results of the parametric NPH Weibull model.
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Figure 6: Comparison of the estimated treatment log-HR from the different models. TOP: The estimated log-hazard ratio of the +24m
AD therapy effects over time, with 95% bounds (smoothed point-wise credible intervals for the MRH model, and point-wise confidence
intervals for the remaining models). In the top left graph, it can be observed that after the initial dip in the NPH Weibull model estimate,
the log-ratio slowly but steadily increases over the course of the study. The 95% confidence interval bounds for the log-HR of the NPH
Weibull model are much narrower than most of the other models, which is expected due to dramatically fewer parameters estimated
in that model. The extended Cox model shows the same upward trajectory, although the initial dip is not pronounced, which is likely
due to the choice of the smoothing parameter. The top right graph shows similarities between the log-HR estimates for the MRH and
adjusted PE models, although the PE models have a sharper upward trend towards the very end of the study. BOTTOM: The estimated
log-hazard ratio of the +24m AD therapy effects over time, with 95% bounds (smoothed point-wise credible intervals for the MRH model,
and approximated point-wise confidence intervals for the AFT and DDP survival models). On the left, the AFT model shows a similar
pattern to the NPH Weibull model, with an initial dip at the beginning of the study, followed by an increasing estimate over time. On
the right, the DDP survival model (calculated on the subset of significant predictors), is contrasted against the NPMRH-3 model (also
calculated on the subset of significant predictors), where they show a similar pattern, with an initial log-HR estimate greater than the
Cox PH estimate, followed by a dip at 2 years. Unlike the other models, the DDP survival model estimated log-HR treatment effect
decreases slightly towards the end of the study. For contrast, the Cox PH model estimated treatment effect and 95% confidence interval
is shown in all figures. All models have periods where the estimated treatment log-HR extends outside the 95% confidence interval for
the Cox PH model treatment effect. The estimated hazard rate and 95% credible interval bounds for the AFT model were predicted for
all covariate groups using the bayessurvreg1() function found in the “bayesSurv” package in R (Koma´rek, 2015), and were predicted
for the DDP survival model using the LDDPsurvival() function in the “DPpackage” package in R (Jara et al., 2012). In both models,
the bounds were used to approximate the point-wise variance of the hazard rates, which were then used to approximate the point-wise
variance of the log-HR.
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Figure 7: LEFT: Comparison of the smoothed, estimated log-hazard ratios for the NPMRH-3 model with k values equal to 0.2, 0.5 (the
default MRH model, denoted with a ‘*’), and 1.0, with estimates shown in black and smoothed point-wise 95% credible interval bounds
shown in grey. The model with k = 0.2 is the least smooth, with the largest 95% credible interval bounds. Conversely, the model with
k = 1 is smoother, with narrower 95% credible interval bounds, as the positive correlation allows more “shared” information between
the hazard increments. RIGHT: The estimated log-hazard ratio for the NPMRH-3 model with k = 10 contrasted with the NPH Weibull
model from the previous section. This figure highlights the adaptability of the MRH model; if k is fixed at a large value (making the
hazard rate quite smooth), the NPMRH-3 model closely mimics the results of the Weibull NPH model. Note that the two figures do not
have the same y-axis scale.
4.2.3 Model Performance Comparison
In addition to model parameter comparisons in Subsection 4.2.1, the set of models were also compared based on their
goodness of fit (GOF), as well as several information criteria. The GOF was evaluated using the following simple
measure over time:
GOF (t) =
1
nt
nt∑
i=1
|Ii{biochemical failure occurs > t} − P (subject i experiences biochemical failure > t)|,
where | · | denotes absolute value, Ii{biochemical failure occurs > t} is an indicator variable which equals 1 if the
subject i fails after time t and equals 0 otherwise, and P (subject i experiences biochemical failure > t) is the model-
based probability of the subject i experiencing biochemical failure. This probability is found based on the estimated
model parameters (posterior medians, or maximum likelihood estimates) and covariates for subject i. Patients who
were censored before time t were not included in the GOF calculation at time t. Therefore, nt represents the total
number of patients in the cohort minus the number of patients censored before time t, so that the maximum value
the GOF statistic can take is 1. In other words, the GOF measure calculates the average difference between the
observed failure time and the probability of failure at that time point. Lower GOF values indicate more accurate
failure approximations and a better fitting model.
Results from the GOF statistic calculations are shown in Figure 8. Most models show very similar results and
trajectories, with exception for both of the adjusted PE models and the extended Cox model. The adjusted PE model
with equal bins has the worst survival prediction initially, followed by the extended Cox model and the adjusted PE
model with bins determined through quantiles. After four years, the extended Cox model has the highest GOF of
all models. Differences between the MRH models (including those with different values of the prior parameter k) are
negligible, and also very similar to the results for the NPH Weibull and AFT models. Note that the GOF statistic
was not calculated for the Cox proportional hazards model, as no estimate of the hazard rate is typically produced
by Cox models. That statistic was also not calculated for the DDP survival model, as subject-specific survival curves
are not provided in that package.
Table 3 shows several information criteria (AIC, BIC, and DIC where appropriate) for all the models considered
(with the exception of the DDP survival model, as subject-specific hazard rates and survival curves are not provided
in that package). Among the MRH models, the PHMRH model has the highest DIC value, which is about 5000
points greater than any of the NPMRH models. It also has the highest negative log-likelihood, BIC and AIC values,
despite the smaller number of parameters when compared to the NPMRH models. This is consistent with our earlier
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Figure 8: LEFT: Goodness-of-fit values across time for both adjusted PE models, the NPH Weibull model, the extended Cox model,
and the AFT model. CENTER: Goodness-of-fit values across time for the four MRH models (PHMRH, NPMRH-0, NPMRH-3, and
NPMRH-6). RIGHT: Goodness-of-fit values across time for the NPMRH-3 model with different fixed k values equal to 0.2, 0.5, 1.0 and
10. The ‘*’ placed by k = 0.5 denotes that this is the original NPMRH-3 model reported above. There are few differences among most
models, with almost indistinguishable differences between the MRH model with all levels pruned and the MRH model with only 3 levels
pruned or the MRH models with different values of k. (Details on the different values of k in the NPMRH models are discussed in section
4.2.2.) However, the extended Cox model and both PE models have higher GOF values for the first seven years when compared to the
others. Note that the GOF statistic was not calculated for the Cox PH model as no estimated hazard rate was available, and was also
not calculated for the DDP survival model, as we did not have access to the subject-specific survival curves.
observation that the PH model does not seem to provide a good description of the data.
When comparing the NPMRH models with different levels of pruning (NPMRH-0, NPMRH-3, NPMRH-6),
the NPMRH-3 model has the lowest negative log-likelihood value, followed closely by the NPMRH-6 model. The
NPMRH-6 model has the lowest DIC, BIC, and AIC values as it has the smallest number of estimated parameters
of all MRH models considered. However, all three NPMRH models have very similar information criteria values,
with the exception of BIC for NPMRH-0 whose penalty for its large number of parameters sets it apart from the
rest of the models. It is also notable that among the NPMRH-3 models, the lowest negative log-likelihood, DIC,
BIC, and AIC values are for the model with k = 0.2, which may be a good choice for examining the hazard rate of
biochemical failure for this particular data set, as it captures the most details in the failure pattern. The negative
log-likelihood values (and hence BIC and AIC calculations) of the adjusted PE models are slightly smaller than
those of the NPMRH models, although the values are comparable. When compared to the NPH Weibull models,
the NPMRH models all have lower negative log-likelihood values. However, BIC and AIC values are higher in the
NPMRH models due to the higher number of estimated parameters. The AFT model has a higher negative log-
likelihood value when compared to the other models (with the exception of the PHMRH model), and the extended
Cox model has a slightly higher negative log-likelihood value when compared to the MRH models, but the values
are similar. Regardless of model choice however, all evidence points to the treatment effects not being proportional:
the effects of an additional 24 months of AD therapy change over the entire length of the study.
5 Discussion
This paper illustrates how different modeling and smoothing assumptions effect the estimate of the time-varying
treatment effect. We present results from a suite of models ranging from parametric to non-parametric, and demon-
strate that different assumptions can lead to very smooth, flat log-hazard ratio estimates (such as those in the NPH
Weibull model) to estimates which vary more over time (such as those in the MRH, PE, and the DDP survival
model). Additionally, the different models exhibited a high degree of variability in the goodness-of-fit measure and
the penalized goodness of fit criteria. We have also shown how choosing different values of k gives the MRH model
the flexibility to perform similarly to other models, ranging from the piece-wise exponential to the parametric Weibull
model. The NPMRH model allows for multiple changes in the treatment effects over time, with multiple increases
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Model -2*log(L) Effective Number DIC BIC AICof Parameters
MRH
PHMRH 12628.0 32 9651.1 12860.3 10555.8
NPMRH-0 4703.1 139 4751.5 5712.1 4981.1
NPMRH-3 4669.8 43 4665.0 4981.9 4755.8
NPMRH-6 4679.0 38 4602.1 4954.8 4755.0
NPMRH-3 (k = 0.2) 4667.9 43 3582.9 4980.1 4753.9
NPMRH-3 (k = 0.5∗) 4669.8 43 4665.0 4981.9 4755.8
NPMRH-3 (k = 1.0) 4700.7 43 4298.7 5012.9 4786.7
NPMRH-3 (k = 10) 4792.8 43 4578.2 5105.0 4878.8
PE Equal bins 4611.1 42 - 4916.0 4695.1Quantile bins 4596.7 56 - 5003.2 4708.7
NPH Weibull 4759.9 11 - 4839.7 4781.9
AFT 5277.9 - - - -
Extended Cox 4747.0 - - - -
Table 3: Information criteria (DIC-when applicable, BIC, and AIC) for the 4 MRH models (PHMRH, NPMRH-0, NPMRH-3, and
NPMRH-6), the NPHMRH-3 model with different fixed values of k (in the Rm,p prior), the non-proportional hazards (NPH) Weibull
model, the adjusted piece-wise exponential models (adjusted by allowing bins to be merged), the AFT model, and the smoothed extended
Cox model. In addition, the values of twice the negative log-likelihood (−2∗ log(L)) and the effective number of parameters (when known)
are shown. Lower DIC, BIC, and AIC values represent models better supported by the data. Details on the different values for k in the
NPMRH models will be discussed in section 4.2.2. The DDP survival model is not included as the log-likelihood and information criteria
values are not available from the fitted model.
and decreases over the length of a study period.
Other patient and disease characteristic covariate effects were similar to those previously seen in this trial
(Horwitz et al., 2008) and expected based on the effects of these factors in other studies. Men with higher Gleason
scores had greater hazard of biochemical failure, although this difference was statistically significant only for those
with Gleason scores of 8 or more. In addition, those with more advanced tumor stage (T-stage 3 or 4) or with
higher PSA level at diagnosis also had a higher hazard rate of biochemical failure. Men who were older at diagnosis
were found to have a lower hazard rate of biochemical failure, although this may be still partly confounded with the
censoring patterns in older patients and warrants further exploration.
Additionally, the presented analysis has allowed insight into the effects of the duration of AD therapy on biochem-
ical failure, and in particular into how the effects of AD therapy changed throughout the course of the study. While
it was already apparent that 24 months of additional AD therapy is beneficial (relative to the 0 additional months
of AD therapy) in that it prolongs the time until biochemical failure and other failure endpoints (Horwitz et al.,
2008), our investigation has revealed additional insights. During and immediately after active therapy, the peak in
the hazard rate around two years is much flatter for the +24m treatment group. In addition, the +24 month group
continued to have a lower hazard rate throughout most of the observation period (over 10 years), although smaller
due to the non-proportionality of the treatment effect. Thus, it does appear that the benefits of the additional months
of AD therapy, while diminishing over time, are persistent, which suggests that failure in the longer AD duration
group are not simply deferred but possibly avoided. On the other hand, for those patients who received short AD
therapy and did not fail early or during the peak period of failures, their late term prognosis is nearly as favorable
as those who underwent long duration AD. Thus, until such patients can be prospectively identified, the long AD
approach would seem to be preferred for all patients. To this end, we also illustrate how the Bayesian approach can
allow the use of posterior predictive failure probabilities, such as in Figure 3, as aids in clinical contexts.
Appendix A: Details on the MRH prior and Pruning Method
MRH prior
The foundation of the MRH method is a tree-like wavelet-based multi-resolution prior on the hazard function, chosen
conveniently to allow scalability and consistency across different time scales (i.e minutes, weeks, years, etc). It uses
a piece-wise constant approximation of the hazard function over J time intervals, parametrized by a set of hazard
increments dj , j = 1, . . . , J . Here, each dj represents the aggregated hazard rate over the j
th time interval, ranging
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from (tj−1, tj). In the standard survival analysis notation, dj =
∫ tj
tj−1
h(s)ds ≡ H(tj) − H(tj−1), where h(t) is the
hazard rate at time t.
To facilitate the recursive diadic partition of the multiresolution tree, we assume that J = 2M . Here, M is an
integer, set large enough to achieve the desired time resolution for the hazard rate. M can also be chosen using model
selection criteria or clinical input, as in Bouman et al. (2005), and Dignam et al. (2009). Note that the cumulative
hazard, H , is equal to the sum of all 2M hazard increments dj , j = 1, . . . 2
M . The model then recursively splits H
at different branches via the “split parameters” Rm,p = Hm,2p/Hm−1,p, m = 1, 2, . . . ,M − 1, p = 0, . . . , 2m−1 − 1.
Here, Hm,q is recursively defined as Hm,q ≡ Hm+1,2q + Hm+1,2q+1 (with H0,0 ≡ H , and q = 0, . . . , 2m − 1). The
Rm,p split parameters, each between 0 and 1, guide the shape of the a priori hazard rate over time (Figure 9).
The complete hazard rate prior specification is obtained via priors placed on all tree parameters: a Gamma(a, λ)
prior is placed on the cumulative hazard H , and Beta prior on each split parameter Rm,p, Be(2γm,pk
ma, 2(1 −
γm,p)k
ma). For example, the priors for H and Rm,p in 3-level MRH model (M = 3, J = 8) would be:
H ∼ Ga(a, λ),
R1,0 ∼ Be(2γ1,0ka, 2(1− γ1,0)ka),
R2,p ∼ Be(2γ2,pk2a, 2(1− γ2,p)k2a), p = 0, 1
R3,p ∼ Be(2γ3,pk3a, 2(1− γ3,p)k3a), p = 0, 1, 2, 3. (2)
Under this parametrization, the prior distribution of each hazard increment is governed by these Beta and Gamma
distributions. In particular, their prior expectations depend on the hyperparameters of the Beta and Gamma
priors – for example, in the above 3-level model E(d1) = E(H)E(R1,0)E(R2,0)E(R3,0). Similarly, these MRH
hyperparameters control the correlation between the hazard increments dj , and thus directly relate to the smoothness
of the multiresolution prior, as shown in Bouman et al. (2005) and Chen et al. (2014). This parametrization also
insures the self-consistency of the MRH prior at multiple resolutions (Bouman et al., 2005; Chen et al., 2014).
Pruning the MRH tree
The MRH prior resolution is chosen as a compromise between the desire for detail in the hazard rate, and the amount
of data. As the resolution increases (and the number of time intervals increases), observed failure counts within each
bin will decrease. While useful for revealing detailed patterns, a large number of intervals (and consequently, a
large number of model parameters) will generally require longer computing times and result in estimators with lower
statistical efficiency (Chen et al., 2014). “Pruning”, as used in Chen et al. (2014), is a data-driven pre-processing
technique, which combines consecutive Hm,ps that are statistically similar (and happens frequently with periods of
low failure counts). The technique increases the computational efficiency by decreasing the parameter dimension
a priori, which can greatly speed up analyses of non-proportional hazards. The pruning method thus changes the
overall time resolution of the MRH prior, keeping the higher resolution during the periods of high event counts, and
lower resolution during periods of low event counts.
The MRH pruning technique has been extensively studied in Chen et al. (2014). Briefly, pruning starts with the
full MRH tree prior, and merges adjacent bins that are constructed via the same split parameter, Rm,p, when the
hazard increments in these two bins (Hm+1,2p and Hm+1,2p+1) are statistically similar. This is inferred by testing
the hypothesis H0 : Rm,p = 0.5 against the alternative Ha : Rm,p 6= 0.5, with a pre-set type I error α, for each split
parameter Rm,p (p = 0, ..., 2
m−1 − 1). If the null hypothesis is not rejected, that split Rm,p is set to 0.5 and the
adjacent hazard increments are considered equal and the time bins declared “fused”. The hypothesis testing can be
applied to all M levels of the tree or just a higher resolution subset of the tree. While the pruning is expected to
reduce the amount hazard rate detail discovered by the MRH method, the posterior hazard rate estimator is shown
to have lower risk compared to its equivalent from the non-pruned model (Chen et al., 2014).
Appendix B: Estimation and Pruning Steps
The estimation algorithm is performed two steps: the pruning step and the Gibbs sampler routine. The details are
listed below.
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Figure 9: Example of an MRH prior mean (black), centered at a desired parametric hazard rate (yellow), at various resolution
levels m. The first figure (upper left) shows the mean MRH rate at the first level (m = 1), with E(H1,0) = E(H) ∗ E(R1,0) and
E(H1,1) = E(H)∗E(1−R1,0). R1,0 prior mean of 0.76 reflects the higher hazard during the first time interval. The second figure (upper
right) shows the mean MRH rate at the second level (m = 2), with E(H2,0) = E(H) ∗ E(R1,0) ∗ E(R2,0), and E(H2,1), E(H2,2) and
E(H2,3) derived analogously. The third figure (lower left), shows the mean MRH rate at the third level (m = 3). The last figure (lower
right), shows the mean MRH rate for m = 6, which closely matches the true hazard rate. In all the figures, the mean MRH rates for the
previous resolutions are shown in grey, E(Rm,p) are shown in green, and E(1 − Rm,p) in red. The advantage of the MRH model is its
“self-consistency” under aggregation (Chen et al., 2014), which means that the prior specification at any level m is independent of the
ultimate level M . This property allows the hazard rate to be examined at multiple resolutions in a consistent manner.
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Pruning step
The pruning step is run only once for each of the L hazard rates at the beginning of the algorithm as a pre-processing
step in order to finalize the MRH tree priors. The Rm,p;ℓ parameters for which the null hypothesis is not rejected
are set to 0.5 with probability 1, while the rest are estimated in the Markov chain Monte Carlo (MCMC) routine.
Gibbs sampler steps
After the pruning step, the Gibbs sampler algorithm is performed to obtain the approximate posterior distribution
of Hℓ, aℓ, λℓ, kℓ, γℓ, and the Rm,p;ℓ that have not been set to 0.5 for each stratum (ℓ = 1, . . . ,L) as well as ~β.
The algorithm is as follows, with steps repeated until convergence:
1. For each of the L treatment hazard rates (ℓ = 1, . . . ,L):
(a) Sample Hℓ from the posterior for Hℓ, which is a gamma density with the shape parameter aℓ+
∑
i∈txℓ
δi,ℓ,
and rate parameter λ−1ℓ +
∑
i∈txℓ
exp
(
X ′i,ℓ
~β
)
Fℓ(Ti,ℓ), where Fℓ(Ti,ℓ) = Hℓ(min(Ti,ℓ, tJ))/Hℓ(tJ ).
(b) Sample aℓ, λℓ from their respective posterior distributions (see below).
(c) Sample each Rm,p;ℓ for which the null hypothesis was rejected from the full conditional:
R
2γm,p;ℓk
m
ℓ aℓ−1
m,p;ℓ (1−Rm,p;ℓ)
2(1−γm,p;ℓ)k
m
ℓ aℓ−1Πi∈txℓ
{
[hℓ0 (Ti,ℓ)]
δi,ℓ exp
(
−exp
(
X ′i,ℓ
~β
)
HℓFℓ(Ti,ℓ)
)}
.
(d) Sample kℓ, γm,p;ℓ from their respective posterior distributions (see below).
2. With a N (0, σ2βs) prior (with a known variance) on each covariate effect modeled under the proportional hazards
assumption, βs (s = 1, . . . , z), each has the following full conditional distribution:
π(βs|β−s ) ∝
(
ΠLℓ=1Πi∈txℓ
[
exp {Xij,ℓβs}
]δi,ℓexp{−exp(X ′i,ℓ~β)HℓFℓ(Ti,ℓ)}) exp
{
−
β2s
2σ2βs
}
Note that this posterior distribution includes the full set of observations and covariates, from all strata jointly.
Full conditionals for the hyperparameters a, λ, k, and γm,p
The parameters in the prior distributions of H and all Rm,ps for each covariate stratum (ℓ = 1, . . . ,L), aℓ, λℓ, kℓ,
and γℓ;m,p, can either be fixed at desired values, or treated as random variables with their own set of hyperpriors.
In the case of the latter, they would be sampled within the Gibbs sampler separately for each stratum, according to
their own full conditional distributions. Below are the forms of these full conditional distributions for a specific set
of hyperpriors we chose.
For notational simplicity, the stratum-specific index is suppressed below. The notation η− will be used to denote
the set of all data and all parameters except for the parameter η itself. The full conditionals are as follows:
• If a is given a zero-truncated Poisson prior,
e−µaµaa
a! (1− e−µa)
(chosen for computational convenience), the full
conditional distribution for a is:
π(a | a−) ∝
Haµaa
λa(a− 1)!a!
ΠMm=1Π
2m−1−1
p=0
{
R
2γm,pk
ma
m,p (1−Rm,p)
2(1−γm,p)k
ma
B(2γm,pkma, 2(1− γm,p)kma)
}
• If the scale parameter λ in the gamma prior for the cumulative hazard function H is given an exponential prior
with mean µλ, the resulting full conditional is:
π(λ|λ−) ∝
1
λa
exp
{
−
(
H
λ
+
λ
µλ
)}
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• If k is given an exponential prior distribution with mean µk, the full conditional distribution for k is as follows:
π(k | k−) ∝ ΠMm=1Π
2m−1−1
p=0
{
R
2γm,pk
ma
m,p (1−Rm,p)
2(1−γm,p)k
ma
B(2γm,pkma, 2(1− γm,p)kma)
}
e
− k
µk
• If a Beta(u, w) prior is placed on each γm,p, the full conditional distribution for each γm,p is proportional to:
R
2γm,pk
ma
m,p (1 −Rm,p)2(1−γm,p)k
ma
B(2γm,pkma, 2(1− γm,p)kma)
γu−1m,p (1 − γm,p)
w−1
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